NYSE$NUVB
Nuvation Bio Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022, and provided a business update.
Nuvation Bio reported a net loss of $21.3 million, or $(0.10) per share for the first quarter ended March 31, 2022. The company had cash, cash equivalents and marketable securities of $737.7 million as of March 31, 2022. The company is focusing on the development of NUV-422, NUV-868, and DDC programs, and has deprioritized NUV-569 and A2A programs.
- NUV-422 on track for initiation of multiple Phase 1b combination and Phase 2 monotherapy cohorts by the end of 2022
- First patient dosed in Phase 1 study of NUV-868 for the treatment of solid tumors
- On track to select first clinical candidate from Drug-Drug Conjugate (DDC) Program by the end of 2022
- NUV-569 and A2A programs deprioritized to focus on development of NUV-422, NUV-868, and DDC programs
Headline financials
Revenue & EPS history
Nuvation Bio · Revenue · Quarterly
$0
Forward guidance
The company expects to share data from the Phase 1 dose escalation study of NUV-422 later this year and plans to initiate Phase 2 monotherapy and Phase 1b combination studies before the end of the year and is on track to select its first clinical candidate for the DDC program by the end of 2022.
Tailwinds
- NUV-422 on track for initiation of multiple Phase 1b combination and Phase 2 monotherapy cohorts by the end of 2022
- First patient dosed in Phase 1 study of NUV-868 for the treatment of solid tumors
- On track to select first clinical candidate from Drug-Drug Conjugate (DDC) Program by the end of 2022
- Nuvation Bio expects to share data from the Phase 1 dose escalation study of NUV-422 later this year.
- The Company plans to initiate the Phase 2 monotherapy and Phase 1b combination studies before the end of the year.
Headwinds
- Challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process
- Difficulties or delays in enrolling subjects or manufacturing or acquiring necessary products
- The emergence or worsening of adverse events or other undesirable side effects
- Risks associated with preliminary and interim data, which may not be representative of more mature data
- Competitive developments
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+1.1%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+9.3%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+16.4%
Q3 2023
Best reaction
-25.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +6.7% | +4.9% | |
| Q4 2025 | -25.2% | -21.4% | -24.5% | |
| Q3 2025 | -6.2% | -8.5% | +60.7% | |
| Q1 2025 | +3.5% | +7.4% | +21.6% | |
| Q4 2024 | +1.0% | +0.0% | +0.5% | |
| Q3 2024 | +12.9% | +29.7% | +22.8% | |
| Q2 2024 | -11.3% | -15.8% | -10.4% | |
| Q1 2024 | -2.1% | -1.5% | -11.3% | |
| Q4 2023 | +13.2% | +10.7% | +84.8% | |
| Q3 2023 | +16.4% | +15.5% | +14.7% | |
| Q2 2023 | +0.5% | +12.0% | -10.4% | |
| Q1 2023 | +4.4% | +0.6% | +6.9% | |
| Q4 2022 | +1.2% | +0.6% | +8.4% | |
| Q3 2022 | -3.7% | -7.4% | -7.8% | |
| Q2 2022 | +7.8% | +12.1% | +26.8% | |
| Q1 2022 | -1.8% | -9.3% | -18.4% | |
| Q4 2021 | -8.3% | -13.7% | +0.8% | |
| Q3 2021 | +3.6% | +6.2% | +4.0% | |
| Q2 2021 | +8.6% | +4.3% | +11.1% | |
| Q1 2021 | +8.9% | +26.7% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro